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Poster Session II S291was faster after PBSCT than BMT (neutrophils 14.5 d versus 18.0 d,
p\0.001; platelets, 23.1 d versus 28.7 d, p5 0.034). The cumulative
incidence of grade II – IV acute graft-versus-host-disease at 100 days
was 10.4% after PBSCT and 15.1% after BMT (p5NS). The cu-
mulative incidence of chronic graft-versus-host disease was 13.8%
after PBSCT and 11.3% after BMT (p5NS). Standard disease
risk was defined as ALL or AML in first or second remission or
with unfavorable prognoses. The high risk category was confined
in third or subsequent remission or in relapse. One year disease-
free survival in standard risk disease was 61.5% after PBSCT and
81.3% after BMT (p5NS). In high risk disease, 1 year survival
was 18.8% after PBSCT and 25.8% after BMT (p5NS). In multi-
variate analysis, only disease risk and pre-transplant CMV seroposi-
tivity were significant predictors of disease-free survival. HLA
typing, CD 34 depletion, and occurrence of acute or chronic
GvHD were included as independent variables but were not signifi-
cant prognostic factors associated with treatment-related mortality,
relapse or disease-free survival. We conclude that PBSCT for chil-
dren produces faster engraftment without increased risk of acute
or chronic GvHD.360
REDUCED-INTENSITY ALLOGENEIC BONE MARROW TRANSPLANTATION
WITHOUT INCLUSION OF TOTAL BODY IRRADIATION FOR A CHILDWITH
DYSKERATOSIS CONGENITA
Powell, J.L., Frantz, C.N., Kolb, E.A. Alfred I. duPont Hospital for Chil-
dren, Wilmington, DE
A 20 month old, ex 33 week gestation male with a history of cere-
bral palsy, retinopathy of prematurity, moderate developmental de-
lay, and periventricular leukoencephalopathy presented during
a febrile episode with a platelet count of 102 k/ml. A CBC obtained
8 months previously had a platelet count of 508 k/ml with otherwise
normal white count and hemoglobin. Over the course of his hospital-
ization, his platelet count fell to 41 k/microliter. His hemoglobin was
10.6 g/dL with an MCV of 93 fL; his white blood cell count was
3.6 k/microliter. His thrombocytopenia continued to worsen, and
he developed neutropenia\750 k/microliter. Physical examination
included dystrophic finger/toe nails. Evaluation for for dyskeratosis
congenita via telomere length measurement was obtained. He was
found to have a median telomere length of 7.9 kb for his lymphocytes
and 8.9 kb for his granulocytes, both of which are very low in com-
parison to laboratory established normals. DKC1, TERC, and
TERT gene evaluations revealed no mutation. Pancytopenia wors-
ened rapidly (hemoglobin \7 g/dL, ANC\0.5 k/microliter,
platelets\10 k/microliter), and we decided to pursue stem cell
transplantation. He received a reduced intensity transplant using flu-
darabine (25 mg/m2/q 24 hours  5 doses on days -7 to -3), cyclo-
phosphamide (400 mg/m2 q 24 hours  4 doses on days -6 to -3),
rabbit ATG (3.75 mg/kg q 24 hours  4 doses on days -5 to -2).
GVH prophylaxis was provided with cyclosporine and methotrexate.
He received a 10/10 matched unrelated bone marrow transplant.
Donor and recipient were both CMV negative. Transplant was
well tolerated by the patient except for allergic reactions to ATG.
The patient experienced grade II skin GVH, treated with cyclospor-
ine and prednisolone. Neutrophil engraftment occurred on day +12;
platelet engraftment occurred on day +25, and red cell engraftment
by day +37. The patient was discharged to home on day +25. Engraft-
ment studies have remained 100% donor from day +12 to the most
recent examination on day +370. The patient has had resolution of
his cytopenias. This patient represents the first US report of
a non-radiation containing, reduced intensity transplant regimen
for a patient with dyskeratosis congenita.361
THE DURATION OF THE EX VIVO TRANSPORTATION OF HEMATOPOIETIC
STEM CELLS DOES NOT SEEM TO IMPAIR THE CLINICAL OUTCOME FOL-
LOWING TRANSPLANTATION – A SINGLE CENTRE STUDY
Olsson, R., Remberger, M., Ringden, O. Karolinska University Hospital,
Stockholm, Sweden
In hematopoietic stem cell transplantation (HSCT), using un-
related donors, stem cells are often harvest at remote hospitals,and may be handled ex vivo for several days before they are in-
fused into the recipient. Thus, the aim of this study was to inves-
tigate whether the duration of the ex vivo transportation of
hematopoietic stem cells impairs the clinical outcome following
transplantation. We retrospectively analyzed 90 consecutive pa-
tients who received unrelated donor hematopoietic stem cells at
our centre between 2003 and 2008. Both children and adults
were included (median age 45, range 0.5-67), whereas retrans-
plantations were excluded. The indications for allogeneic
HSCT were: AML (32%), ALL (16%), myelodysplastic syn-
drome (16%), CML (10%), lymphoma (12%), solid tumors
(7%), metabolic disorders (3%), aplastic anemia (2%), and multi-
ple myeloma (2%). In all recipients, the total ex vivo time of the
stem cell transplant (median 28 h, range 5-53 h) was calculated
and subdivided into the transportation time from the donor hos-
pital to our centre (median 20 h, range 3-38 h), as well as the
time from arrival at our hospital until the start of the stem cell
infusion (median 10 h, 0.5-26 h). In univariate analysis, none of
the ex vivo times were significant predictors of graft failure, re-
lapse, non-relapse mortality or overall survival. In conclusion,
the clinical outcome following HSCT seems to be independent
of the time the stem cell transplant is kept ex vivo for transpor-
tation purposes.362
HIGH RABBIT-ANTI-HUMAN THYMOCYTE GLOBULIN SERUM LEVELS
ARE ASSOCIATED WITH LOW LIKELIHOOD OF GRAFT-VS-HOST DISEASE
AND HIGH LIKELIHOOD OF POSTTRANSPLANT LYMPHOPROLIFERATIVE
DISORDER
Ugarte-Torres, A.1, Podgorny, P.J.1, Liu, Y.1, Russell, J.A.2, Storek, J.2
1University of Calgary, Calgary, AB, Canada; 2Alberta Health Services,
Calgary, AB, Canada
Background: Rabbit-anti-human T cell globulin (ATG) has the po-
tential to decrease the likelihood of graft-vs-host disease (GVHD) or
graft failure and to increase the likelihood of relapse or infections.
After a given ATG dose, serum ATG levels are variable, presumably
due to variable clearance.
Patients andMethods:We determined ATG levels on day 7 and 28
in 160 recipients of allogeneic marrow or blood stem cells, whose
conditioning included 4.5 mg/kg ATG (Thymoglobulin, Genzyme).
Median follow up was 419 days (range, 14-1519).
Results: Patients with grade 2-4 acute GVHD as well as patients
with extensive chronic GVHD had lower and patients with post-
transplant lymphoproliferative disorder (PTLD) had higher median
ATG levels on day 7 as well as day 28. In multivariate analysis, pa-
tients with day 7 ATG levels above 1.109 mg/ml had 0.38-fold risk
of developing grade 2-4 acute GVHD compared to patients with
lower ATG levels (p5 0.02), patients with day 7 levels above
0.673 mg/ml had 0.44-fold risk of developing extensive chronic
GVHD (p5 0.009), and patients with day 7 ATG levels above
1.436 mg/ml had 8.30-fold risk of developing PTLD (p5 .001).
There was no association of either day 7 or day 28 ATG levels
with relapse, non-PTLD infections or death. Association with graft
failure could not be evaluated due to only 4 graft failures in the
cohort.
Conclusion: Patients with slow clearance of ATG have a low risk of
acute and chronic GVHD but a high risk of PTLD.363
EARLY COMPLETE DONOR LYMPHOID CHIMERISMWITH FLUDARABINE,
MELPHALAN AND LOW DOSE (400 CGY) TOTAL BODY IRRADIATION RE-
DUCED INTENSITY CONDITIONING
Hepgur, M.1, Saito, N.2, Hahn, T.2, Starostik, P.3, Wallace, P.4,
Bambach, B.2, Higman, M.2, Dubel, K.2, McCarthy, P.2,
Battiwalla, M.2 1University at Buffalo, Buffalo, NY; 2Roswell Park Can-
cer Institute, Buffalo, NY; 3Roswell Park Cancer Institute, Buffalo, NY;
4Roswell Park Cancer Institute, Buffalo, NY
Background: Delayed acquisition of complete donor lymphoid
chimerism may contribute to relapse in 200 cGy total body
S292 Poster Session IIirradiation based (TBI) reduced intensity conditioning regimens
for allogeneic hematopoietic cell transplant (alloHCT). We pres-
ent results of the first 10 patients receiving a novel conditioning
regimen comprising fludarabine 40 mg/m2/day  four, melpha-
lan 50 mg/m2  one and TBI 200 cGy  two fractions. The
goal of this reduced intensity regimen was to achieve complete
rapid complete donor lymphoid chimerism in order to promote
graft vs. malignancy effects without excess regimen related
toxicity.
Methods: Ten consecutive patients, six male and four female,
underwent reduced intensity conditioning followed by alloHCT.
The median age was 51.5 (range 5-71). Diagnoses and patient
numbers were myelodysplastic syndrome (MDS), n5 3,acute
myeloid leukemia (AML), n5 3, Non-Hodgkin lymphoma
(NHL), n5 3 and Diamond Blackfan anemia, n5 1. Stem cell
sources peripheral blood (PB), n5 8 and bone marrow, n5 2.
Donors were related n5 8 of which n were HLA matched
and unrelated, n5 4 which  were HLA matched at  loci.
Three patients were undergoing second transplants (second
allo n5 1) and prior autoHCT (n5 2). Three patients had un-
controlled malignancy at the time of transplant. The extent of
donor chimerism was assessed by flow-sorting PB for myeloid
(CD33) and lymphoid (CD3) markers followed by short tandem
repeat (STR) analysis.
Results: At a median follow up 88 days (range 14-171); nine of ten
recipients were alive at day 30. One patient died on day fifteen
post transplant with progressive disease. Six of nine patients achieved
complete donor lymphoid chimerism and seven of nine patients
achieved complete donor myeloid chimerism in peripheral blood
day 30. This is significantly faster than historical controls using
200 cGy based regimens. Of the three patients who had incomplete
donor chimerism, two had refractory malignancy (AML or MDS) at
the time of transplant and the third patient developed progressive
MDS soon after. Treatment related mortality at day 100 was ten per-
cent. One of the ten patients manifested grade 3-4 Bearman regimen
related toxicity.
Conclusions: Reduced intensity with Flu/Mel/TBI 400 is well tol-















Malignancy#1 128 30 100 100 No Yes
#2 58 27 100 100 No No
#3 104 30 100 100 No No
#4 98 34 100 100 No No
#5 77 33 94 75 No No
#6 171 27 95 95 Yes No
#7 78 34 100 100 No No
#8 100 30 100 100 No Yes
#9 30 30 92 100 No No
#10 14 died
day 15
NA NA Yes Yes364
A STEM CELL POTENCY, QUALITY AND RELEASE (PQR) ASSAY FOR UM-
BILICAL CORD BLOOD THAT IS COMPLIANT WITH REGULATORY GUIDE-
LINES
Rich, I.N., Hall, K., Harper, H. HemoGenix, Inc, Colorado Springs, CO
New guidelines and regulations in the U.S.A. and Europe will
require that the cell potency of cellular and gene therapy products
are determined prior to their intended use in the patient. Umbil-
ical cord blood (UCB) is a cellular therapeutic product whose po-
tency and release criteria will fall under these criteria. The presentparameters of total nucleated cell (TNC) count, viability, CD34
and CFU not only fall significantly short of what would be re-
quired, but are used post-processing, pre-cryopreservation rather
than post-thaw prior to transplantation. Furthermore, none of
these tests determine stem cell ‘‘quality’’ or potency, which is
a measure of stem cell engraftment potential (EP). The CFU as-
say, as used by the UCB community, measures the differentiation
(not proliferation) of GM progenitors, which have no stem cell
properties and therefore can only detect engraftment outcome,
i.e. time to neutrophil engraftment, but not EP. An in vitro, in-
strument-based, ATP bioluminescence potency, quality and re-
lease (PQR) assay that can be fully validated for the intended
use has been developed and tested. 24 UCB samples were tested
for proliferation status (‘‘quality’’) and potential (potency) of 2
stem cell populations, 1 primitive (HPP-SP) and the other mature
(CFC-GEMM), each at 3 cell doses, and the response compared
to the same cell populations from a UCB reference standard.
The results showed that the assay is .90% effective in predicting
EP. Testing a single stem cell population (CFC-GEMM) can lead
to a false interpretation, but a duel stem cell potency assay can
provide greater predictive value for short- and long-term EP.
Stem cell ‘‘quality’’ should also be determined using duel popula-
tions, since together with potency, acceptance limits for release
criteria can be defined. The PQR assay is a powerful and predic-
tive tool that, together with other assays, can provide the trans-
plantation decision-maker with information that has, until now,
not been possible.365
THIOTEPA (TT), BUSULFAN (BU), AND CLOFARABINE (CLO) AS A CONDI-
TIONING THERAPY FOR ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANT FOR PATIENTS WITH HIGH RISK MALIGNANCIES: EARLY
RESPONSE AND ENGRAFTMENT DATA
Worth, L.L.1, Andersson, B.S.2, Kazerooni, R.3, Petropoulos, D.1,
Kelly, S.S.1, Lee, D.A.1, Du, M.1, Madden, T.L.3, deLima, M.J.2,
Champlin, R.E.2, Cooper, L.J.N.1 1M.D. Anderson Cancer Center, Hous-
ton, TX; 2M.D. Anderson Cancer Center, Houston, TX; 3M.D. Anderson
Cancer Center, Houston, TX
Introduction: Fludarabine (F) and Busulfan (Bu) are commonly
used together in transplantation conditioning regimens. To im-
prove on this combination, we substituted Clofarabine (Clo) for
F for its improved antileukemic activity. In addition, we added
Thiotepa (TT) as a polyfunctional alkylating agent recognized
for its antileukemic activity and its ability to cross the blood
brain barrier. We investigated TT+ (IV) Bu + Clo as a condition-
ing regimen for advanced malignancies using a variety of stem
cell sources.
Methods: Patients (pts) received TT 5 mg/kg over 1 hr on d -8. Bu
was given IV over 3 h to a daily AUC of 5,000 mcMol-min +/-10%
on d -5 to -3. Clo 40 mg/m2 was infused over 1 hr daily on d -6 to -3.
All 9 pts are evaluable for engraftment and survival beyond d +30. M/
F: 4/5. Median age was 22 (range 6-60). Five pts had AML [relapse
refractory/Flt3+/3rd transplant, CR1 h/o leptomeningeal disease,
MDS/AML (CR2), CR4 (3rd BMT) and CR7 (3rd BMT)]. Others
had T-cell PLL (2), ALL (CR3), CLL (3rd relapse-refr). GVHD pro-
phylaxis was tacrolimus and mini-MTX or tacrolimus and MMF
[cord blood (CB) recipients]. Those with one Ag-mism or unrelated
grafts received rabbit-ATG. Stem cell sources included cord (4 db
CB; 1 single CB); MUD-apheresis (2), MUD-BM (1), MSD-apher-
esis (1).
Results: All pts engrafted neutrophils at a median of 14 d (10-25),
and platelets at a median of 42 d (CB) and 12 d (PB/BM), respec-
tively. 8 of the 9 pts are $60 days post transplantation, and the re-
maining pt  30 days. Esophagitis (max grade 2) was the most
common regimen related toxicity (RRT). Transient, mild hyperbilir-
ubinemia from RRT occurred in 5 pts. (med 3.6 mg/dl; range
2 – 9.1). Deaths (2) were due to GVHD (d +56) and infection (d
+56). Two pts relapsed (d +59, d +87). PB microsatellite chimerism
around day +30 showed 100% donor-derived T cell and myeloid
cells in 8 pts. One had mixed chimerism (3% recipient T cells).
